Chemomab Therapeutics
CMMB
13 hedge funds and large institutions have $615K invested in Chemomab Therapeutics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
11% more capital invested
Capital invested by funds: $552K → $615K (+$63.4K)
0.39% more ownership
Funds ownership: 4.89% → 5.28% (+0.39%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
13% less funds holding
Funds holding: 15 → 13 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$52.5K |
| 2 |
Lido Advisors
Los Angeles,
California
|
+$24.2K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$20.5K |
| 4 |
PIP
Philadelphia Investment Partners
Voorhees,
New Jersey
|
+$11.5K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SP
SmartHarvest Portfolios
Poulsbo,
Washington
|
-$22.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$21.2K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
-$4.79K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$4.45K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$2.73K |
CMMB Hedge Fund Activity: Q2 2026 in Review
13 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q2 2026, worth a combined $615K — up 11% from $552K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CMMB and 1 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Citadel Advisors, adding an estimated $52.5K. The largest seller was SmartHarvest Portfolios, exiting entirely with an estimated $22.9K sold.
- 13 institutional investors held Chemomab Therapeutics (CMMB) as of Q2 2026, down from 15 in Q1 2026.
- Funds reported $615K of Chemomab Therapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 1 fund opened new Chemomab Therapeutics positions in Q2 2026 and 3 closed out, a net change of -2 holders.
- The largest Chemomab Therapeutics buyer in Q2 2026 was Citadel Advisors, an estimated $52.5K added.
- The largest Chemomab Therapeutics seller in Q2 2026 was SmartHarvest Portfolios, an estimated $22.9K sold.
Based on aggregated 13F filings for Q2 2026.